NOVALIQ SUBMITS NEW DRUG APPLICATION SEEKING APPROVAL FOR FIRST-OF-A-KIND DRY EYE DISEASE TREATMENT CYCLASOL® (English only)
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for CyclASol® (cyclosporine ophthalmic solution), a proposed novel treatment for the signs and symptoms of dry eye disease (DED).